Evidence map›Paper›PMID 35884094›Full record

ArticleAntibiotics (Basel, Switzerland)2022

The Optimal Permeation of Cyclic Boronates to Cross the Outer Membrane via the Porin Pathway.

Gian Marco Tuveri, Matteo Ceccarelli, Alessandro Pira, Igor V Bodrenko

Open access · goldAbstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 3 countries.

Gian Marco TuveriMolecular Bionics, Institute for Bioengineering of Catalonia, Carrer de Baldiri Reixac, 10, 12, 08028 Barcelona, Spain.ORCID 0000-0002-3463-1279
Matteo CeccarelliDipartimento di Fisica, University of Cagliari, Cittadella Universitaria, Monserrato, 09042-IT Cagliari, Italy.ORCID 0000-0003-4272-902X
Alessandro PiraDipartimento di Scienze Chimiche e Geologiche, University of Cagliari, Cittadella Universitaria, Monserrato, 09042-IT Cagliari, Italy.ORCID 0000-0003-3380-4403
Igor V BodrenkoCentro Nazionale di Ricerca/Istituto Officina dei Materiali (CNR/IOM), Sezione di Cagliari, c/o Dipartimento di Fisica, Cittadella Universitaria, Monserrato, 09042-IT Cagliari, Italy.ORCID 0000-0003-1141-1449
University of Cagliari · ITConstructor University · DEInstitute for Bioengineering of Catalonia · ES

Funding

Innovative Medicines Initiative 115525
6 · The paper itself

Abstract

We investigated the diffusion of three cyclic boronates formulated as beta-lactamase inhibitors through the porin OmpF to evaluate their potential to cross OM via the porin pathway. The three nonbeta-lactam molecules diffuse through the porin eyelet region with the same mechanism observed for beta-lactam molecules and diazobicyclooctan derivatives, with the electric dipole moment aligned with the transversal electric field. In particular, the BOH group can interact with both the basic ladder and the acidic loop L3, which is characteristic of the size-constricted region of this class of porins. On one hand, we confirm that the transport of small molecules through enterobacter porins has a common general mechanism; on the other, the class of cyclic boronate molecules does not seem to have particular difficulties in diffusing through enterobacter porins, thus representing a good scaffold for new anti-infectives targeting Gram-negative bacteria research.

Indexed as

beta-lactamase inhibitorscyclic boronatesdiffusion currentmetadynamicsmolecular dynamics simulationspermeationporins

Identifiers

PMID35884094
PMCPMC9311757
OpenAlexW4283391601

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.